Groowe
/
Newsroom
/ DSGN
⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DSGN
News
Design Therapeutics, Inc. Common Stock
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
globenewswire.com
Nov 5, 2025 10:02 PM
DSGN
← Newer
Page 2 of 2
Older →
